设为首页         

资讯内容 Content

[ESC2009]单片复方制剂(SPC)倍博特在高血压治疗中的应用和优势--Weir教授专访
国际循环网版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。

 编辑:国际循环网 时间:2009/9/3 18:26:00    加入收藏
 关键字:单片复方制剂 高血压治疗 倍博特 阿利吉仑 

International Circulation:  In a previous article of yours, you have mentioned that single pill combination is a good choice for patients who need two or more than 2 antihypertension medications to reach target blood pressure. What would be the advantages of a valsartan amlodipine single pill combination (Exforge®) for antihypertensive therapy?

《国际循环》:您在您以往的文章中曾经提到,单片药物联合是那些需要两种或两种以上抗高血压药物才能达到目标血压的患者的一个良好选择。那么缬沙坦氨氯地平单片(Exforge®)在抗高血压治疗中有何优势?

Professor Weir:  More and more we are realizing now that most patients need more than one medication to get their blood pressure to appropriate diastolic and systolic blood pressure goals.  The recommendation really is today if you are more than 20mm from your goal, you should start two medications and if you can, preferably as a single pill combination.  I think the unique aspects of combining an angiotensin receptor blocker like valsartan and a calcium channel blocker like amlodipine is that these two individual medicines are the most commonly prescribed in their respective groups for the treatment of high blood pressure.  So it seems natural to combine two of the most popular medications we use for blood pressure in a single pill for the many people who require more than one.

Weir教授:我们现在正越来越多的意识到,为使血压达到适当的收缩压和舒张压水平,大多数患者需要不止一种药物。当前的推荐是,如果患者血压较目标血压高出超过20 mm Hg,就应当起始采用两种药物联合治疗;如果可以的话,最好是以单片联合的形式。 我认为,将血管紧张素受体拮抗剂如缬沙坦与钙通道阻滞剂如氨氯地平联合的一个独一无二的特点是,这两种药物本身在其各自的种类中均是最常被处方用于高血压治疗的药物。因此,将这两种最常用的高血压治疗药物联合在单个片剂中用于很多需要不止一种药物的患者看起来是种很自然的做法。

 

浏览访谈视频



[1]  [2]  [3]  [4]  [5]  [6]  下一页

   评论发言          
 
京ICP备15014970号-5   国际循环 版权所有  2008-2022 icirculation.com  All Rights Reserved